<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476554</url>
  </required_header>
  <id_info>
    <org_study_id>CYC682-06-05</org_study_id>
    <nct_id>NCT00476554</nct_id>
    <nct_alias>NCT00475995</nct_alias>
  </id_info>
  <brief_title>A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open label, randomized phase II study designed to evaluate the tolerability and
      response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell
      lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2
      systemic therapies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual and financial resource limitation
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate in overall skin disease</measure>
    <time_frame>over the course of study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cutaneous T-cell Lymphoma (CTCL)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapacitabine</intervention_name>
    <description>Sapacitabine</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with advanced CTCL

          -  Have had at least 2 systemic therapies

          -  Must have evaluable disease

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Adequate bone marrow, hepatic and renal function

          -  At least 3 weeks from prior therapies

          -  Not receiving topical steroids or have been on a stable dose of topical steroids for
             at least 2 weeks

          -  Able to swallow capsules

          -  At least 3 weeks from major surgery

          -  Agree to practice effective contraception

          -  Able to understand and willing to sign the informed consent form

        Exclusion Criteria:

          -  Receiving systemic steroids

          -  Receiving topical or systemic retinoids or vitamin A

          -  Receiving radiotherapy, biological therapy,or any other investigational agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  Active hepatitis B and/or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy H Chiao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cyclacel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timothy Kuzel, M.D.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2007</study_first_submitted>
  <study_first_submitted_qc>May 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

